WBB Securities upgraded CohBar from Speculative Buy to Buy and set a new price target of $5.00

Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00

Aegis Capital initiated coverage of CohBar with a rating of Buy and set a new price target of $6.00

Gainers 180 Life Sciences (NASDAQ:ATNF) shares rose 38.2% to $0.47 during Tuesday's after-market session. The company's market cap stands at $3.4 million. Redhill Biopharma (NASDAQ:RDHL) shares rose 23.34% to $2.8. The market value of their outstanding shares is at $30.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 15.25% to $0.52. The company's market cap stands at $19.8 million. Blue Water Biotech (NASDAQ:BWV) shares increased by 13.04% to $0.26. The market value of their outstanding shares is at $4.8 million. CohBar (NASDAQ:CWBR) shares increased by 12.96% to $0.86. The market value of their outstanding shares is at $2.4 million. DermTech (NASDAQ:DMTK) stock moved upwards by 9.

Shares of SenesTech, Inc. (NASDAQ:SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. SenesTech company priced a public offering of around 3.8 million shares of common stock at $1.30 per share, alongside warrants for additional shares. SenesTech shares declined 50.3% to $0.9189 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers IceCure Medical Ltd (NASDAQ:ICCM) jumped 90% to $1.44 after the company announced the latest release of a study in a series of independent studies of ProSense published in peer-reviewed journals demonstrating safety and efficacy. RedHill Biopharma Ltd. (NASDAQ:RDH

Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 38.1% to $8.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $630.6 million. Heart Test Laboratories (NASDAQ:HSCS) shares moved upwards by 22.98% to $0.26. The market value of their outstanding shares is at $12.8 million. Redhill Biopharma (NASDAQ:RDHL) shares moved upwards by 17.99% to $1.18. The company's market cap stands at $13.0 million. icad (NASDAQ:ICAD) shares increased by 17.51% to $1.61. The market value of their outstanding shares is at $42.4 million. Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 10.81% to $0.25. The market value of their outstanding shares is at $4.5 mil

Shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults with desmoid tumors. SpringWorks Therapeutics shares rose 14.4% to $23.77 in pre-market trading Here are some other stocks moving in pre-market trading. Gainers SaverOne 2014 Ltd (NASDAQ:SVRE) shares rose 74.8% to $0.7389 in pre-market trading. SaverOne announced withdrawal of proposed public offering due to market conditions. ESGL Holdings Limited (NASDAQ:ESGL) shares rose 54.3% to $1.38 in pre-market trading after the company disclosed a multi-year contract renewal with Singapore Refini

CohBar Inc (NASDAQ:CWBR) shares are trading lower by 47% to $0.92 Wednesday afternoon. The stock is falling sharply after the company received guidance from Nasdaq that the company and Morphogenesis, Inc's merger agreement would not be approved. What Else? After discussions, CohBar decided that there was no viable way to proceed with the merger, and Morphogenesis issued a termination notice in accordance with the agreement. Consequently, CohBar plans to liquidate and dissolve itself. As of September 30, 2023, CohBar says the company had around $9.1 million in cash, cash equivalents and investments, along with approximately $1.5 million in accrued liabilities. The exact amount available t

Gainers Cellectis S.A. (NASDAQ:CLLS) shares jumped 136% to $2.2799. Cellectis reported strategic collaboration and investment agreements with AstraZeneca. Cellectis also presented pre-clinical data on multi-armored allogeneic MUC1-CAR T-cells targeting triple-negative breast cancer at the Society for Immunotherapy of Cancer 38th Annual Meeting. Patriot Transportation Holding, Inc. (NASDAQ:PATI) climbed 104.8% to $15.73. Patriot Transportation announced an agreement under which United Petroleum Transports will acquire all of the outstanding shares of Patriot common stock for $16.26 per share in cash. Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) gained 33% to $2.2780. Aldeyra Therapeutics e

Gainers Cellectis (NASDAQ:CLLS) shares moved upwards by 188.6% to $2.8 during Wednesday's regular session. Trading volume for this security as of 13:31 EST is 58.7 million, which is 110697.6% of its average full-day volume over the last 100 days. The company's market cap stands at $155.6 million. Aldeyra Therapeutics (NASDAQ:ALDX) shares rose 50.74% to $2.58. Aldeyra Therapeutics's stock is trading at a volume of 58.1 million shares as of 13:31 EST. This is 5356.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $151.0 million. Monopar Therapeutics (NASDAQ:MNPR) stock increased by 37.51% to $0.59. As of 13:31 EST, this security is

-SEC 8K Filing

-SEC 8K Filing

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)

MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp

IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

TAMPA, FL / ACCESSWIRE / May 30, 2023 / Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ:CWBR) ("CohBar"), today announced that Morphogenesis' abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL. Details of the presentation are as follows:Title: Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma a

TAMPA, Fla. and MENLO PARK, Calif., May 30, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology company developing novel personalized cancer vaccines and tumor microenvironment modulators to overcome resistance to current immunotherapies, and CohBar, Inc. (NASDAQ:CWBR) ("CohBar"), today announced that Morphogenesis' abstract has been accepted for poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 in Chicago, IL. Details of the presentation are as follows: Title: Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor re

Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M

MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i

MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: November 8, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.

MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the "Board") has approved a 1-for-30 reverse stock split of the company's common stock. The reverse stock split will become effective at 12:01am ET on September 23, 2022 and begin trading on a split-adjusted basis at the market open on September 23, 2022 with the new CUSIP number 19249J 307. The company is implementing the reverse stock split to enable

25-NSE - CohBar, Inc. (0001522602) (Subject)

8-K - CohBar, Inc. (0001522602) (Filer)

8-K - CohBar, Inc. (0001522602) (Filer)

8-K - CohBar, Inc. (0001522602) (Filer)

425 - CohBar, Inc. (0001522602) (Subject)

8-K - CohBar, Inc. (0001522602) (Filer)

425 - CohBar, Inc. (0001522602) (Subject)

8-K/A - CohBar, Inc. (0001522602) (Filer)

425 - CohBar, Inc. (0001522602) (Subject)

8-K - CohBar, Inc. (0001522602) (Filer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

3 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

4 - CohBar, Inc. (0001522602) (Issuer)

MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovative biotechnology companies. "We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clini

Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar's founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the company's Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other dis

MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chair

MENLO PARK, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Carol Nast as an independent director on the company's Board, effective August 11, 2021. Ms. Nast has spent her career in executive level positions with both large multinational companies and early-stage companies in the medical industry. "We are pleased to welcome Carol during this exciting time in CohBar's development," said David Greenwood, Chairman of CohBar. "She brings substantial commercial and operational expertise that will bene

MENLO PARK, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today reported its financial results for the second quarter ended June 30, 2021. "Our positive CB4211 topline data announcement today marks an important milestone in our path towards demonstrating the full potential of our novel therapeutic platform sourced from the mitochondrial genome," stated Dr. Joseph Sarret, Chief Executive Officer. "In parallel with our ongoing analysis of the promising data from the CB4211 study, we are diligently working to enable CB5138-3 to enter

MENLO PARK, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joseph J. Sarret, M.D., J.D. as Chief Executive Officer and Director, effective May 3, 2021. The Board of Directors expresses appreciation for the contribution of Mr. Steven Engle during his tenure as CEO and Director of the company. In addition, Mr. David Greenwood, a current Director with 40 years of financial and operational experience in biotechnology and investment banking, has assumed the role of Chairman of the Board. "We are pleas

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M

MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i

MENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: November 8, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.

IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highlighted recent corporate progress. "We remain excited about the opportunity for CB5138-3 and its potential to make a significant impact on the treatment of IPF. During the prior quarter, we continue

MENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 second quarter financial results after the market closes on Monday, August 15, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: August 15, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.S.

MENLO PARK, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the first quarter ended March 31, 2022 and highlighted recent corporate progress. "I am optimistic about the year ahead and the opportunity we have at CohBar to develop therapies for difficult to treat, multi-factorial diseases. In 2022, we remain focused on execution and with a strong team in place, we are well positioned to advance our mitochondrial programs an

MENLO PARK, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 first quarter financial results after the market closes on Monday, May 16, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: May 16, 2022Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio -  Dial-in U.S. and

MENLO PARK, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2021 fourth quarter and full year financial results after the market closes on Tuesday, March 29, 2022. Management will host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: March 29, 2022Time: 5:00 p.m. ET (2:00 p.m. PT)  Conference Audio

MENLO PARK, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, announced today that the company will release its third quarter 2021 financial results after the market closes on Monday, November 15, 2021. Management will host a conference call at 5:00 p.m. ET (2:00 p.m. PT) on the same day to provide an update on the company's business. Details for the Conference Call: Date: November 15, 2021Time: 5:00 p.m. ET (2:00 p.m. PT) Conference Audio Dial-in U.S. and Canada: (844) 825-9789Dial-in International: (412) 317-5180Conference ID No.